Generated by AI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing cancer therapies that target nuclear export, a cellular process involved in disease biology. Its core technology centers on small-molecule inhibitors of exportin 1, or XPO1, designed to disrupt the movement of proteins and genetic material between the cell nucleus and cytoplasm. The company’s marketed product, XPOVIO (selinexor), is used in combination treatment for certain adults with multiple myeloma and as a treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm also evaluates selinexor across additional hematologic and solid-tumor indications, including myelofibrosis and endometrial cancer, while advancing other selective nuclear export inhibitor compounds such as eltanexor. Headquartered in Newton, Massachusetts, Karyopharm operates within the oncology biotechnology market, serving healthcare providers and patients through prescription medicines targeting cancers with significant treatment needs.
Website85 Wells Avenue
Newton, MA, 02459-3298
United States
The latest articles about KPTI.
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.
Summary of Nov 10's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Summary of Aug 6's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Investors talking about KPTI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.